Heart Failure/Transplantation
Review | Restrictive cardiomyopathy: definition and diagnosis.
24 Oct, 2022 | 13:58h | UTCRestrictive cardiomyopathy: definition and diagnosis – European Heart Journal
Commentary on Twitter
⚠️Great review ? Restrictive cardiomyopathy
?definition
?diagnosis
?therapies available only for cardiac amyloidosis and, for iron overload cardiomyopath?? https://t.co/OtO7L45SBw pic.twitter.com/L55mPnmNtt
— Alfonso Valle (@ValleAlfonso) October 22, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ License
M-A | Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes.
19 Oct, 2022 | 14:11h | UTC
Position Statement | Use of biomarkers for the management of heart failure and acute coronary syndrome.
17 Oct, 2022 | 12:34h | UTC
A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction.
17 Oct, 2022 | 12:15h | UTC
Review | Heart failure after right ventricular myocardial infarction.
14 Oct, 2022 | 14:05h | UTCHeart Failure After Right Ventricular Myocardial Infarction – Current Heart Failure Reports
Cohort Study | A collaborative home-based palliative care intervention for patients with heart failure reduced the risk of dying in the hospital.
13 Oct, 2022 | 13:37h | UTCCommentary: Home-Based Palliative Care for Heart Failure May Cut Risk for Dying in Hospital – HealthDay
Commentary on Twitter
Patients who received home-based, interdisciplinary palliative care were more likely to die at home than in hospital, compared to those who received usual care: https://t.co/JsLvANgcPK@kieranlquinn @PTanuseputro @sarina_isenberg #PalliativeCare #HeartFailure pic.twitter.com/6rOPtYQw2h
— CMAJ (@CMAJ) September 26, 2022
Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications.
11 Oct, 2022 | 13:33h | UTC
RCT | Riociguat improved hemodynamics but increased dropouts in pulmonary hypertension and HFpEF.
11 Oct, 2022 | 13:26h | UTC
Commentary on Twitter
Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: results of randomized, double-blind, placebo-controlled, multicentre trial out.https://t.co/FYmorikQR5#HFpEF #HF #cardiotwitter @ESC_Journals @escardio pic.twitter.com/4sSeYt7Adq
— EHJ Editor-in-Chief (@ehj_ed) October 7, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Cohort Study | Albuminuria as a marker of systemic congestion in patients with heart failure.
7 Oct, 2022 | 14:19h | UTC
Brief Review | How do we maximize diuresis in acute decompensated heart failure?
5 Oct, 2022 | 13:51h | UTC
Cohort Study | Cardiovascular MRI phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis.
30 Sep, 2022 | 12:39h | UTCCardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis – JAMA Cardiology (link to abstract – $ for full-text)
Commentary on Twitter
Cardiovascular magnetic resonance phenotypes could be used to optimize clinical decision-making for treatment options, such as implantable cardioverter-defibrillators, and thus improve outcomes in patients with suspected cardiac #sarcoidosis. https://t.co/6hlpPFd7cd #Research
— JAMA Cardiology (@JAMACardio) September 14, 2022
ACEP Clinical Policy | Critical issues in the management of patients presenting to the ED with acute heart failure syndromes.
27 Sep, 2022 | 13:20h | UTC
Consensus Paper | Renal effects of guideline-directed medical therapies in heart failure.
27 Sep, 2022 | 13:13h | UTC
Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy.
26 Sep, 2022 | 11:57h | UTC
Commentary on Twitter
Is it possible to predict which pts w/ dilated cardiomyopathy/left ventricular dysfunction will have an assoc. predisposition on genetic testing?
Via the Madrid Score, Drs. @LuisEscobarL, @dr_pavia, & colleagues work to answer this question in #JACC: https://t.co/WDn8jA29aY pic.twitter.com/u0T9FffOwi
— JACC Journals (@JACCJournals) September 13, 2022
M-A | Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction.
22 Sep, 2022 | 13:05h | UTCRelated M-A: SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (link to abstract – $ for full-text)
A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.
20 Sep, 2022 | 13:16h | UTCA Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction – JAMA Cardiology (link to abstract – $ for full-text)
Commentary on Twitter
This cohort study found that a simple 6 variable clinical score may be used to guide use of PYP and increase recognition of cardiomyopathy (ATTR-CM) among patients with HFpEF in the community. https://t.co/2fzCZf97Mp #Research
— JAMA Cardiology (@JAMACardio) September 7, 2022
Guideline Synopsis | AHA/ACC Guideline for the management of heart failure.
16 Sep, 2022 | 13:01h | UTCManagement of Heart Failure – JAMA (free for a limited period)
Original Article: #ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Retrospective Cohort Study | Natural history of MYH7-related dilated cardiomyopathy.
14 Sep, 2022 | 13:06h | UTC
Five-year outcomes in patients with fully magnetically levitated vs. axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial.
11 Sep, 2022 | 22:43h | UTCFive-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial – JAMA (free for a limited period)
Commentary on Twitter
Among patients with advanced #heartfailure, receipt of a fully magnetically levitated centrifugal-flow LVAD vs axial-flow LVAD was associated with a better composite outcome and higher likelihood of overall survival at 5 years. #Research https://t.co/S0KdHp0tAO
— JAMA (@JAMA_current) September 8, 2022
Large study unravels the risk factors for heart failure among childhood cancer survivors.
11 Sep, 2022 | 22:22h | UTC
#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related:
#ESCCongress – RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.
29 Aug, 2022 | 12:38h | UTCPercutaneous Revascularization for Ischemic Left Ventricular Dysfunction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Coronary stenting does not benefit patients with severe left ventricular dysfunction – European Society of Cardiology
Commentary on Twitter
REVIVED-BCIS2: In patients with a low left ventricular ejection fraction and viable myocardium, PCI did not reduce the incidence of death from any cause or hospitalization for heart failure. #ESCCongress https://t.co/XtZlkJ7GAf pic.twitter.com/6uMNemzkyN
— NEJM (@NEJM) August 27, 2022
#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.
29 Aug, 2022 | 12:35h | UTCSGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)
Commentary on Twitter
Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y— Kieran Docherty (@Kieranfdocherty) August 27, 2022
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
29 Aug, 2022 | 12:25h | UTCAcetazolamide in Acute Decompensated Heart Failure with Volume Overload – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Acetazolamide improves decongestion in patients with acute decompensated heart failure – European Society of Cardiology
Commentary: Acetazolamide in Decompensated Heart Failure With Volume Overload – ADVOR – American College of Cardiology
Commentary on Twitter
ADVOR: In a placebo-controlled trial, patients with acute decompensated heart failure and volume overload who had been randomly assigned to receive IV acetazolamide plus a loop diuretic had a higher incidence of decongestion. #ESCCongress https://t.co/YeoffDhXwc pic.twitter.com/YV3gM3gxij
— NEJM (@NEJM) August 27, 2022